CIRM Caps Off $237 Million in Clinical Stage Funding as It Reexamines Its Priorities
$26 million in awards last week is the last for 2023-24
California’s stem cell and gene therapy program awarded four companies and one academic scientist a total of $26 million last week for clinical research into rare diseases, heart disease and cancer.
The awards brought the number of clinical trials backed by CIRM to 108.
The companies are Mahzi Therapeutics of San Francisco, Rejuvenate Bio of San Diego, Rocket Pharmaceuticals, Inc., of New Jersey and Senti Bio of South San Francisco. Abedi Mehrdad of UC Davis is the academic.
CIRM highlighted two awards: the ones for
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.